Monthly Archives: September 2012

Space station on alert

Posted: September 28, 2012 at 12:11 am

Plans to move the International Space Station to a slightly different orbit were called off on Thursday after controllers determined that two pieces of orbital debris would not pose a collision risk, NASA said.

Mission controllers had been monitoring debris from an old Russian Cosmos satellite and a fragment from an Indian rocket, and said there was a chance that the debris could come close enough to require an adjustment in the station's orbit on Thursday.

Space news from NBCNews.com

Science editor Alan Boyle's blog: A fresh picture from NASA's Curiosity rover shows the Martian moon Phobos as a crescent shining over the Red Planet at dusk.

But NASA said additional tracking of the debris "resulted in a high degree of confidence that neither object would pose any possibility of a conjunction" with the station. As a result, Mission Control in Houston canceled the debris avoidance maneuver. Russian flight controllers endorsed the decision, NASA said.

Space junk moves so fast that it can puncture the station, so engineers try to give debris a wide berth whenever something comes close. Three spacefliers NASA's Sunita Williams, Russia's Yuri Malenchenko and Japan's Akihiko Hoshide are currently living aboard the station.

If the maneuver had been required, the engines of a European cargo ship docked to the station, the Edoardo Amaldi Automated Transfer Vehicle, would have been fired to make the move. A communications glitch kept the unmanned ATV from leaving the station earlier this week, as scheduled.

"Russian engineers told mission managers that they fully understand the nature of the error and are prepared to proceed to a second undocking attempt," NASA said in Thursday's update. The tentative plans for the debris avoidance maneuver meant the next attempt to undock the ATV had to be delayed until Friday at the earliest.

Once the craft is undocked, a pair of engine firings will send it down through the atmosphere to burn up over the Pacific Ocean.

This report includes information from NBC News and The Associated Press.

View post:
Space station on alert

Posted in Space Station | Comments Off on Space station on alert

Jackson Lab CEO Leads From Heart

Posted: at 12:11 am

BAR HARBOR Edison Liu, M.D. has filled top leadership positions across the globe while gaining encyclopedic knowledge of cancer pathology, human genetics and medical science. But one year into his term as president and CEO of the Jackson Laboratory, Dr. Liu has become known for something decidedly artistic; the good doctor is actually one heck of a piano player.

Music runs strong through Dr. Lius life, from his childhood in California, through his recent, decade-long stint as the founding executive director of the Genome Institute of Singapore. It didnt take long for others at the lab to take notice of his skills. A monthly pick-up session in Roscoes, the labs cafeteria, soon developed, with Dr. Liu taking the lead on the house piano.

Theres only one prerequisite to play, Dr. Liu told the Islander in a wide-ranging interview this week, and that is an adherence to what he calls sincere art. In other words, you may not be very good, but you have to be very sincere.

When filtered through Dr. Lius impressive intellect, those monthly jam sessions resonate with meaning. Music, he said, provides alternative communication pathways, ones that are able to break through much of the stalemate that can develop out of modern life. Musical sincerityis the closest thing to truth that I know of, he said.

There is a different etiquette, an opening of different portals into the heart, Dr. Liu said. And the more pathways we have into each others souls, the closer community we have.

A search for those pathways defines Dr. Lius leadership style and traces the arc of his career. From the time he was five years old, he wanted to be a physician, just as his parents were. But just as music, and the great literature that Dr. Liu also loves, tells a sometimes unexpected story, so, too, has Dr. Lius path in life.

See the article here:
Jackson Lab CEO Leads From Heart

Posted in Human Genetics | Comments Off on Jackson Lab CEO Leads From Heart

New drive to take criminals' DNA

Posted: at 12:11 am

27 September 2012 Last updated at 13:20 ET

Police forces in England and Wales have begun a large-scale operation to collect DNA samples from about 12,000 serious offenders who are not on the national DNA database.

Operation Nutmeg will see officers collect swabs from sex offenders and murderers living in the community.

Criminals are often not on the database if they were convicted before 1994, when sample-taking became routine.

The scheme has been launched after a successful pilot exercise in Hampshire.

Police hope the collection of thousands of new samples could help to solve so-called cold-cases, where a new sample is linked to a past crime.

Speaking at a briefing on Thursday, Amanda Cooper, director of information, science and technology at Thames Valley Police, said officers would approach individuals between now and next summer to collect the samples.

Police forces have been given lists of offenders living in their areas and will work though them to collect the samples.

The lists have been drawn up based on information from the Police National Computer, which was first used in the 1970s.

Alex Marshall, the chief constable of Hampshire police, said 167 samples were taken from a list of 471 convicted criminals during the pilot operation.

Continued here:
New drive to take criminals' DNA

Posted in DNA | Comments Off on New drive to take criminals' DNA

Many female brains contain male DNA

Posted: at 12:11 am

In the first study of its kind, researchers have discovered that male DNA is commonly found in the brains of women a finding that could hold important implications for diseases like Alzheimers disease and cancer.

Male DNA is likely transferred to female brains during pregnancy, according to researchers from the Fred Hutchinson Cancer Research Center in Seattle. During this time, mothers and fetuses exchange and harbor genetic material and cells in a phenomenon called microchimerism.

This means, if a mother is pregnant with a boy, she will end up with male DNA in her system potentially for the rest of her life. If the fetus is female, the mother will end up with genetic material from her daughter, though it is difficult for researchers to distinguish between two sets of female DNA in microchimerism studies.

What this means for treating diseases

Prior studies have observed fetal DNA in many other of the mothers tissues and organs, but this is the first to confirm fetal cells can cross the blood-brain barrier and reside in the mothers brain beyond pregnancy.

We were interested in looking at the human brain because its never been looked at before, and it was really unknown if the cells of fetal origin could reach the brain, study senior author Dr. Lee Nelson, a member of the Fred Hutchinson Cancer Research Center and professor of medicine at the University of Washington, told FoxNews.com. Nelson and her colleagues performed autopsies on 59 brains of deceased females and detected male microchimerism in 63 percent of them.

Male microchimerism was distributed across multiple regions of the female brain, including those affected by dementia, and could persist for decades potentially even an entire human lifespan. According to the study, the oldest female with microchimerism detected in her brain was 94.

The question naturally arises what role might the cells have in benefiting health and what role they play in diseases, Nelson added.

The researchers hope further studies on microchimerism might shed new light on various diseases that affect the brain, such as Alzheimers, Parkinsons or even brain tumors.

These cells have access to the brain could help us understand different treatment options for diseases that arent well treated, Nelson said. Its a very exciting new area that opens up different possibilities, such as, what if these cells have anti-tumor potential? For example, glioblastomas are deadly tumors, (which) have poor treatment options. Were very much in need of new potential options.

View original post here:
Many female brains contain male DNA

Posted in DNA | Comments Off on Many female brains contain male DNA

Bearing Sons Leaves Male DNA Traces in Mom's Brain

Posted: at 12:11 am

By Melissa Lee Phillips, ScienceNOW

Giving a whole new meaning to pregnancy brain, a new study shows that male DNA likely left over from pregnancy with a male fetus can persist in a womans brain throughout her life. Although the biological impact of this foreign DNA is unclear, the study also found that women with more male DNA in their brains were less likely to have suffered from Alzheimers disease hinting that the male DNA could help protect the mothers from the disease, the researchers say.

During mammalian pregnancy, the mother and fetus exchange DNA and cells. Previous work has shown that fetal cells can linger in the mothers blood and bone for decades, a condition researchers call fetal microchimerism. The lingering of the fetal DNA, research suggests, may be a mixed blessing for a mom: The cells may benefit the mothers health by promoting tissue repair and improving the immune system but may also cause adverse effects, such as autoimmune reactions.

One question is how leftover fetal cells affect the brain. Researchers have shown that fetal microchimerism occurs in mouse brains, but they had not shown this in humans. So a team led by autoimmunity researcher and rheumatologist J. Lee Nelson of the Fred Hutchinson Cancer Research Center in Seattle, Washington, took samples from autopsied brains of 59 women who died between the ages of 32 and 101. By testing for a gene specific to the Y chromosome, they found evidence of male DNA in the brains of 63 percent of the women. (The researchers did not have the history of the womens pregnancies.) The male DNA was scattered across multiple brain regions, the team reports online today in PLoS ONE.

Because some studies have suggested that the risk of Alzheimers disease (A.D.) increases with an increasing number of pregnancies, the team also examined the brains for signs of the disease, allowing them to determine whether A.D. correlated with the observed microchimerism. Of the 59 women, 33 had A.D. but contrary to the teams expectation, the women with A.D. had significantly less male DNA in their brains than did the 26 women who did not have A.D..

Whether that correlation means that fetal male DNA helps protect women against A.D. is unclear, however. To me, this suggests that the presence of fetal cells in the female brain prevents disease, says cardiologist Hina Chaudhry of Mount Sinai School of Medicine in New York City.

In a study published online in Circulation Research late last year, Chaudhry and colleagues found that fetal cells in mice migrated to the mothers heart, differentiated into functioning cardiac cells, and accelerated repair to damaged heart tissue. So, Chaudhry says, a similar thing could be happening when fetal cells migrate to the brain. I would bet these cells are getting into the maternal brain and are able to differentiate into neurons.

A 2010 study in Stem Cells and Development showed that fetal cells can migrate to the brain of a mother mouse and mature into neurons, Nelson says. But, she adds, it remains unclear if something similar is happening in humans and its also difficult to reach any firm conclusions about a potential link between microchimerism and A.D. Part of the problem is that her team had little information about the pregnancy histories of the women in their study. We have to say we really dont know, she says. I hope that kind of work can be done in the future, but its very difficult to do with human samples.

This story provided by ScienceNOW, the daily online news service of the journal Science.

Excerpt from:
Bearing Sons Leaves Male DNA Traces in Mom's Brain

Posted in DNA | Comments Off on Bearing Sons Leaves Male DNA Traces in Mom's Brain

BGI@CHOP Joint Genome Center to Offer Clinical Next-Generation Sequencing Services

Posted: at 12:11 am

A Joint News Release from The Childrens Hospital of Philadelphia and BGI

Newswise September 27, 2012, Philadelphia and Shenzhen, China The Childrens Hospital of Philadelphia (CHOP) and BGI announced today that the BGI@CHOP Joint Genome Center will begin to offer clinical next-generation sequencing (NGS) services at CHOP through the hospitals Department of Pathology and Laboratory Medicine in a CAP/CLIA-compliant environment.

The Clinical Laboratories Improvement Act of 1988 (CLIA) established quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed. The College of American Pathologists (CAP) Laboratory Accreditation Program is widely recognized as the gold standard, since it meets or exceeds CLIA requirements and serves as a model for various federal, state, and private laboratory accreditation programs throughout the world.

Supported by CHOPs and BGIs excellent infrastructure and extensive experiences in NGS services, the BGI@CHOP Joint Genome Center was established in Nov. 2011 under the partnership between CHOP and BGI to focus on discovery of genes underpinning rare and common pediatric diseases using next-generation sequencing.

Robert W. Doms, M.D., Ph.D., pathologist-in-chief and chair of Pathology and Laboratory Medicine at CHOP, said, The BGI@CHOP Joint Genome Center, operating under the umbrella of the CAP-certified Molecular Genetics Lab at CHOP, plans to launch clinical exome sequencing in the near future.

Catherine Stolle, Ph.D., director of CHOPs Molecular Genetics Laboratory, added, This CAP- compliant NGS facility will enable us to rapidly expand into clinical NGS tests for diagnosis of specific diseases including heritable disorders and pediatric cancer. "BGI has been offering NGS and NGS data analysis services in a research setting since 2007," Dr. Jun Wang, Executive Director of BGI, said in a statement. "By working together with the CHOP Pathology Department, we will be able to leverage our NGS expertise to help clinicians better diagnose and treat their patients. BGI will also be able to extend our services to support new drug development and pharmaceutical clinical trial studies in compliance with CAP and CLIA standards.

At present, the Joint Genome Center is equipped with 5 high-throughput sequencers with the permanent space under renovation, and plans to scale up to 20 sequencers. The center has embarked on a number of projects with CHOP researchers, including an NIH-funded research grant to explore the use of NGS in a clinical diagnostic setting (co-led by Ian Krantz, M.D., and Nancy Spinner, Ph.D.). The Centers service portfolio includes human whole exome sequencing, targeted sequencing, whole genome re-sequencing, specialized applications such as ChIP-Seq and RNA-Seq, and NGS data analysis.

About The Childrens Hospital of Philadelphia The Childrens Hospital of Philadelphia was founded in 1855 as the first pediatric hospital in the United States. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide and its pediatric research program is among the largest in the U.S. In addition, its unique family-centered care and public service programs have brought the 516-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

About BGI BGI was founded in Beijing, China, in 1999 with the mission to become a premier scientific partner for the global research community. The goal of BGI is to make leading-edge genomic science highly accessible, which it achieves through its investment in infrastructure, leveraging the best available technology, economies of scale, and expert bioinformatics resources. BGI, which includes both private non-profit genomic research institutes and sequencing application commercial units, and its affiliates, BGI Americas, headquartered in Cambridge, MA, and BGI Europe, headquartered in Copenhagen, Denmark, have established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, supporting a variety of disease, agricultural, environmental, and related applications.

BGI has a proven track record of excellence, delivering results with high efficiency and accuracy for innovative, high-profile research: research that has generated over 200 publications in top-tier journals such as Nature and Science. BGIs many accomplishments include: sequencing one percent of the human genome for the International Human Genome Project, contributing 10 percent to the International Human HapMap Project, carrying out research to combat SARS and German deadly E. coli, playing a key role in the Sino-British Chicken Genome Project, and completing the sequence of the rice genome, the silkworm genome, the first Asian diploid genome, the potato genome, and, more recently, the human Gut Metagenome, as well as a significant proportion of the genomes for the1000 Genomes Project. For more information, please visit http://www.genomics.cn. or http://www.bgiamericas.com

Read more from the original source:
BGI@CHOP Joint Genome Center to Offer Clinical Next-Generation Sequencing Services

Posted in Genome | Comments Off on BGI@CHOP Joint Genome Center to Offer Clinical Next-Generation Sequencing Services

Forget the Cloud—Knome Offers Genome Analysis in a Box

Posted: at 12:11 am

Starting today, researchers can now order a "plug-and-play" human genome interpretation system from Knome, the Cambridge, Massachusetts-based genome analysis company co-founded by Harvard Medical School's George Church. The nearly 600-lb box of computer hardware that is pre-loaded with genomic interpretation software sells for $125,000 and is designed to simplify the task of gleaning useful medical information from a patient's DNA.

The "lab in a box" model contrasts with a program underway at genomics giant Illumina, which plans to enable customers to upload their DNA sequences to a cloud-based data storage and analysis system for interpretation. And selling a product that integrates hardware and software together is a new move for Knome, which has previously provided genomeanalysisas a service to customers who send in their samples or raw DNA data. So why would Knome want to move into the hardware distribution business?

As reported by GenomeWeb Daily News, the idea for an integrated system grew from discussions the company had with early users of its KnomeClinic software,which is design to help health-care professionals interpret genomic data (see "Knome Software Makes Sense of the Genome"). The reasons seem to be two-fold: security concerns over the medical information and the lack of good IT support at some medical institutions.

Martin Tolar, Knome's CEO, said that these early-access users .... had a number of recommendations, but the primary one was that "they wanted a solution that was within the four walls of the institution for privacy and regulatory reasons."

Initially, he said, "we were considering having enterprise software that would be installed at each of the institutions, but it became very clear that not everybody had the hardware and the capabilities to run such a complicated system. And also, [we decided that] if we can optimize the hardware for the software that we've built, it's going to be much more effective and efficient. So that's why we decided to put it all in one box."

See the original post:
Forget the Cloud—Knome Offers Genome Analysis in a Box

Posted in Genome | Comments Off on Forget the Cloud—Knome Offers Genome Analysis in a Box

Priority Health: Eczema

Posted: at 12:11 am

Gloria says, I had eczema as a child, then it went away and now I am a senior and it is back. What do you do for it?

Unfortunately, Gloria, not a lot has changed in the treatment for eczema since you we're a child. Eczema is a chronic skin condition that causes dry itchy patches usually around the elbows and knees, but in reality, it can be found almost anywhere you have skin. It was originally thought to be related to asthma or hay fever (allergies) but now we really don't think so. It is probably an immune problem, with something in the environment acting as a trigger. It usually comes and goes, and can start as an infant, persist through adolescence, and disappear for years only then to reappear and start all over again.

Symptoms:

Since this is a chronic condition, treatment is mainly to reduce the symptoms. You can expect "flares", especially when under stress, throughout your lifetime.

Treatment options:

The immunomodulators are really the only new type of treatment available. They have been found to be effective, but have some significant side effects if used for extended periods of time. They are recommended for only short duration. As with anything chronic, there are always triggers that make the symptoms worse. Avoiding the triggers is often the best treatment.

Triggers:

As you can see, the triggers are everywhere! BUT, not everyone has the same triggers, so look for the ones that are specific for you. If you can avoid the problem, there is no need for any expensive or strong treatment with side effects! Stay Healthy My Friends!

Read this article:
Priority Health: Eczema

Posted in Eczema | Comments Off on Priority Health: Eczema

Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe …

Posted: at 12:11 am

Phase II data show AIN457 given weekly during the first month of treatment improved hand/foot psoriasis at Week 12 (54% of patients vs 19% on placebo)[1] AIN457 selectively binds to and inhibits interleukin-17A, a key driver of immune-mediated diseases and a promising target for the next generation of therapy[2-4] AIN457 pivotal Phase III trials with more than 3,000 psoriasis patients on track with regulatory submissions expected in 2013 Psoriasis on the hands, feet and nails is traditionally difficult-to-treat, causes functional and social disability and can affect up to 55% of psoriasis patients[5],[6]

Basel, September 27, 2012 - Novartis announced today new Phase II data showing AIN457 (secukinumab) may significantly improve moderate-to-severe plaque psoriasis on the hands, feet and nails when used every week for the first month of treatment, compared to placebo[1],[7]. Additional analysis on patients with moderate-to-severe plaque psoriasis also showed that AIN457 may successfully improve quality of life by Week 12 in the study[8].

"These new AIN457 data are particularly welcome since they demonstrate significant improvement in the signs and symptoms of patients, even when difficult-to-treat areas are involved," said Prof. Kristian Reich, one of the study investigators and Professor of Dermatology, Venereology, and Allergology in Hamburg, Germany. "Many patients with hand, foot or nail psoriasis are restricted in their daily life and work because they may not be able to walk or use their hands, negatively impacting their quality of life."

The results will be presented today at the European Academy of Dermatology and Venereology (EADV) 21st Congress, in Prague, Czech Republic. They provide additional insight into the safety and efficacy of AIN457, following the presentation of the study`s primary endpoint at EADV in 2011.

The new data from the sub-analyses undertaken on the Phase II study show AIN457 was nearly three times more effective than placebo at reducing moderate-to-severe plaque psoriasis on the hands and/or feet when given every week during the first month of treatment (54.3% of patients vs. 19.2% respectively, p=0.005), as measured by the Investigator`s Global Assessment (IGA)[1]. Patients also benefited if they received AIN457 once every four weeks, with 39.0% experiencing either "clear" or "minimal" psoriasis after 12 weeks of treatment[1]. Another analysis found that these AIN457 treatment schedules also notably reduced the signs and symptoms of finger nail psoriasis compared to placebo[7].

The study safety analysis of these data showed a comparable safety profile between treatment and placebo, with the most common adverse events (AEs) observed being infections[1],[7].

Other new data presented at EADV in the total moderate-to-severe plaque psoriasis study population show that AIN457 improved skin-related quality of life in 25 times more patients after 12 weeks of treatment when given every week for the first month, compared to placebo (40.8% vs. 1.6%, p<0.001), as measured by the Dermatology Life Quality Index (DLQI)[8]. In this same treatment group, significantly more patients experienced improvements in pain and discomfort compared to placebo (36.2% vs. -1.5%) from baseline; and in anxiety and depression versus placebo (16.3% vs. 6.2%), as measured by EuroQol (EQ-5D)[8]. The effect of psoriasis on patients` health-related quality of life has been shown to be similar to diseases such as cancer, heart attack, arthritis, type 2 diabetes and depression[9].

"These encouraging results show that through its novel mode of action, AIN457 may significantly increase treatment success and improve the quality of life of patients suffering from moderate-to-severe plaque psoriasis," said John Hohneker, Head of Development for Integrated Hospital Care for the Pharmaceuticals Division of Novartis. "We look forward to receiving the results of the larger-scale and longer-term Phase III studies, which are expected in 2013."

All core pivotal trials for AIN457 in moderate-to-severe plaque psoriasis are on track, involving more than 3,000 patients worldwide, and indicating a high interest from both medical and patient communities. Phase III data in moderate-to-severe plaque psoriasis is expected in 2013, with regulatory submissions to follow shortly thereafter.

About the study Data are based on a double-blind, parallel group, placebo-controlled Phase II study involving 404 patients, which met its primary endpoint of PASI 75 (Psoriasis Area and Severity Index) responses at Week 12[10]. It was designed to evaluate the safety and efficacy of AIN457 in different regimens (weekly for the first month; once every four weeks; or single dose) of 150 mg given subcutaneously[10].

Read the rest here:
Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe ...

Posted in Psoriasis | Comments Off on Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe …

Novartis Psoriasis Drug Shows Promising Results

Posted: at 12:11 am

Editor's Choice Main Category: Eczema / Psoriasis Also Included In: Dermatology Article Date: 27 Sep 2012 - 10:00 PDT

Current ratings for: Novartis Psoriasis Drug Shows Promising Results

Novartis added that the patients on secukinumab enjoyed improved quality of life by the twelfth week of therapy.

Prof. Kristian Reich, one of the study investigators said:

The AIN457 (secukinumab) trial results were presented today at the European Academy of Dermatology and Venereology (EADV) 21st Congress, in Prague, Czech Republic.

According to new data on the Phase II trial, AIN457 is almost three times as effective than placebo in alleviating moderate-to-severe plague psoriasis on the hands, feet and nails during the first month of treatment (54.3% versus 19.2% on placebo). Novartis added that "patients also benefited if they received AIN457 once every four weeks, with 39.0% experiencing either "clear" or "minimal" psoriasis after 12 weeks of treatment. Another analysis found that these AIN457 treatment schedules also notably reduced the signs and symptoms of finger nail psoriasis compared to placebo."

The most common adverse events reports were infections.

Other data include:

John Hohneker, Head of Development for Integrated Hospital Care for the Pharmaceuticals Division of Novartis, said:

The AIN457 pivotal human studies for the treatment of moderate-to-severe plaque psoriasis are "on track", the company says. The trials, involving over 3,000 participants, are attracting interest among both patients and health care professionals. Novartis says it will be releasing data on the Phase III trials in 2013. Soon after, if the data is favorable, submissions to regulatory authorities will be presented.

Read more here:
Novartis Psoriasis Drug Shows Promising Results

Posted in Psoriasis | Comments Off on Novartis Psoriasis Drug Shows Promising Results